Advancing Investigational
Photo Neuromodulation for Parkinson’s Disease
Celeste® is an investigational device being studied to better understand the role of
retinal and circadian signaling pathways in Parkinson’s disease.
Addressing Major Unmet Needs
in Parkinson’s Disease
Parkinson’s disease affects more than 11 million people worldwide, a number expected to grow significantly in the coming decades. While advances in symptom management have helped many people live longer and more active lives, substantial unmet needs remain.
Many individuals living with Parkinson’s disease experience challenges that extend beyond movement, including sleep disturbances, fatigue, mood changes, cognitive difficulties, and disruptions to daily life. These symptoms can significantly impact independence, wellbeing, and overall quality of life.
PhotoPharmics was founded to explore whether targeted light-based interventions may influence biological pathways involved in neurological function. The company’s research focuses on the relationship between light-responsive retinal pathways, circadian biology, and the brain.
Celeste® is an investigational photo-neuromodulation device being evaluated for Parkinson’s disease. Through a series of clinical studies, PhotoPharmics has explored the potential role of this approach in addressing important unmet needs within the Parkinson’s community.
We are grateful to the participants, caregivers, investigators, researchers, and advocates who have contributed to this work and invite you to follow our ongoing scientific and regulatory journey.
Light for PD Trial Completed
Receive updates regarding the Celeste® clinical and regulatory program
Seeing Photo-Neuromodulation Clearly
Celeste® is an investigational photo-neuromodulation device being evaluated for Parkinson’s disease.
SCIENCE-BASED
Built upon research exploring how light-responsive retinal pathways communicate with broader neurological systems.
NON-INVASIVE
Designed to deliver light through the eyes
without surgery or implanted hardware.
HOME-BASED
Developed for use in a familiar home environment
as part of ongoing clinical research.
LATEST UPDATES
PhotoPharmics to Participate in AAN Annual Meeting as Phase 3 Light for PD Trial Nears Completion
Company available for scientific exchange as pivotal study approaches completion. Data Readout Anticipated at World Parkinson Congress. SALT LAKE CITY, UT, UNITED STATES, April 16, 2026 /EINPresswire.com/ -- PhotoPharmics, a clinical-stage medical device company...
PhotoPharmics Announces Publication of Phase 2 Clinical Trial Results in Neurotherapeutics and Its Role in the Company’s Phase 3/Pivotal Clinical Trial
Peer-reviewed Phase 2 Results Inform Ongoing Phase 3/Pivotal Trial of Celeste® in Parkinson’s Disease PhotoPharmics, Inc. today announced the peer-reviewed publication of results from its Phase 2 randomized, double-blind, controlled clinical trial evaluating Celeste®,...
Understanding Parkinson’s Fatigue
Introduction Imagine waking up after a full night’s sleep, yet feeling as though you haven’t slept in days. Your limbs feel heavy, as if you are moving through molasses, and the mental effort required to simply plan your day feels akin to solving complex calculus. ...
PhotoPharmics Announces Board Expansion to Support the Next Phases of Growth: Clinical Execution, Commercialization, and Strategic Partnerships
PhotoPharmics, a clinical-stage medical device company developing photo-neuromodulation therapies for neurodegenerative diseases today announced the addition of two widely respected industry leaders to its Board of Directors: W. James W. Tozer, Jr. and Albert Agro,...
The Role of Nutrition in Parkinson’s Disease
Introduction Did you know that unintentional weight loss and nutritional deficiencies are among the most common challenges for people with Parkinson’s disease, often occurring even before a diagnosis is made? In simple terms, Parkinson’s Disease is a condition where...